Article Details

ArriVent's $175M Upsized IPO Builds Momentum on Heels of CG Oncology Offering

Retrieved on: 2024-01-26 21:21:58

Tags for this article:

Click the tags to see associated articles and topics

ArriVent's $175M Upsized IPO Builds Momentum on Heels of CG Oncology Offering. View article details on HISWAI: https://www.biospace.com/article/arrivent-s-175m-upsized-ipo-builds-momentum-on-heels-of-cg-oncology-offering/

Summary

ArriVent Biopharma, targeting Biopharma sector, notably lung cancer, has raised $175 million in its IPO to advance furmonertinib, an EGFR inhibitor for non-small-cell lung cancer, addressing oncogenic mutations like T790M.

Article found on: www.biospace.com

View Original Article

This article is found inside other Hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up